Abstract
To the Editor.— Freeman et al 1 , in their article Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome, state that the symptoms were not significantly improved by progesterone compared with placebo. Dalton 2 has shown that, in 1096 patients, only 23% responded to a dose as low as 400 mg daily, 33% responded to a dose of 400 mg twice daily, and another 20% responded to 400 mg three times daily, with 46% of the sample requiring a dose higher than 400 mg of progesterone twice daily. Maddock et al 3 noted the variation of content of the progesterone suppositories. When 14 different types of progesterone suppositories from the United States were analyzed, only one was within the 3% limit required by the Committee of Safety in Medicines in Britain, and six ranged between 57% and 34% of the stated content. Freeman et al make no mention of the patient's
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JAMA: The Journal of the American Medical Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
